Dual antitumour effect of 5-azacytidine by inducing a breakdown of resistance-mediating factors and epigenetic modulation by Venturelli, S. et al.
Dual antitumour effect of 5-azacytidine by inducing
a breakdown of resistance-mediating factors and
epigenetic modulation
Sascha Venturelli,1 Alexander Berger,1 Timo Weiland,1 Martina Zimmermann,1
Sabine Ha¨cker,2 Christoph Peter,1 Sebastian Wesselborg,1 Alfred Ko¨nigsrainer,3
Thomas S Weiss,4 Michael Gregor,1 Simone Fulda,2 Ulrich M Lauer,1 Michael Bitzer1
ABSTRACT
Background The cytokine tumour necrosis factor-related
apoptosis-inducing ligand (TRAIL) has shown promising
anticancer activity in early clinical settings by selectively
inducing apoptosis in different tumour types. However,
some tumour entities such as hepatocellular carcinoma
(HCC) display an inherent resistance to TRAIL. A huge
effort has been made to unravel strategies for a clinically
applicable sensitisation of resistant cancer cells to TRAIL.
Reversible epigenetic alterations such as DNA
methylation play a major role in development,
maintenance and resistance phenomena of tumour cells.
Currently, several clinical trials are exploiting the
potential of epigenetic drugs, such as 5-azacytidine
(5-aza-CR) or 5-aza-29-deoxycytidine (5-aza-dC) to break
primary or secondary resistance phenomena of cancer
cells. Therefore, 5-aza-CR and 5-aza-dC were
investigated in the context of TRAIL resistance.
Methods Alterations in proliferation, apoptosis,
regulatory proteins and toxicity were investigated in
TRAIL-resistant hepatoma, and also in renal, colon and
pancreatic cancer cells as well as non-transformed
human-derived primary hepatocytes, tissue slices
isolated from human liver and non-malignant colon cells,
all of which had been exposed to demethylating drugs
and/or TRAIL.
Results Within hours, 5-aza-CR but not 5-aza-dC
sensitised in vitro cultured tumour cells to TRAIL, first by
activating caspases, followed by a subsequent induction
of apoptosis. This surprisingly rapid sensitisation was
confirmed in vivo employing a chorioallantoic membrane
assay. As a major mechanism, a 5-aza-CR-induced
inhibition of cellular protein synthesis was found which
led to a breakdown of tumour-protecting factors such as
the antiapoptotic factor FLICE inhibitory protein (FLIP).
Importantly, TRAIL and 5-aza-CR did not induce relevant
toxicity or apoptosis in primary hepatocytes, liver slices
from different human donors and in normal colon cells.
Conclusions Molecular evidence is provided for a novel
5-aza-CR-based translational approach enabling a twofold
treatment of apoptosis-resistant tumour entities, not only
by an epigenetic reversion of the malignancy-associated
phenotype but also by an efficient resensitisation to
apoptosis-inducing substances such as TRAIL.
INTRODUCTION
For decades no substantial progress could be
achieved in the treatment of advanced hepatocel-
lular carcinoma (HCC). Resistance phenomena
prevented the development of new treatment
strategies. Sorafenib, a multikinase inhibitor, was
the ﬁrst substance for which a modest survival
beneﬁt could be proven recently2; however, new
therapeutic principles are urgently needed to
improve further the perspective of patients with
HCC. Two innovative approaches in this context
are the modulation of epigenetic alterations in
tumour cells and the application of tumour-selec-
tive cytokines such as the tumour necrosis factor-
related apoptosis-inducing ligand (TRAIL).
Epigenetic alterations play a major role in the
development and maintenance of HCC and also
other tumour entities with a hypermethylation of
CpG islands speciﬁcally within promotor regions of
cellular control genes, inducing their functional
shut-down.3e5 These alterations constitute
a highly interesting therapeutic target because of
< Additional figures and
Materials and methods are
published online only. To view
these files please visit the
journal online (http://gut.bmj.
com).
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Significance of this study
What is already known about this subject?
< Epigenetic alterations play a major role in the
development and maintenance of hepatocellular
carcinoma (HCC) and other tumour entities with
a hypermethylation of CpG islands specifically
within promotor regions of cellular control
genes, inducing their functional shut-down.
< Epigenetic alterations constitute a highly
interesting therapeutic target because of their
potential reversibility.
< The two most advanced epigenetic drugs to
reverse aberrant methylation events in cancer
cells are 5-azacytidine (5-aza-CR, Vidaza) and
5-aza-29-deoxycytidine (5-aza-dC, Decitabine,
Dacogen). These are today the only DNA
methyltransferase inhibitors with FDA approval
and are used for the treatment of myelodys-
plastic syndrome and acute myeloid leukaemia.
< The current interest in the proapoptotic signalling
of TRAIL in cancer cells is reflected by the fact
that at least six different TRAIL receptor-targeted
therapeutics (antibodies/recombinant proteins)
have already been tested in clinical trials.
< Apoptosis-resistant cancer cells comprise
a major problem in clinical oncology requiring
clinically applicable drugs, which efficiently
interfere with apoptosis-protecting factors (very
recently reviewed by Schulze-Bergkamen et al1).
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their potential reversibility. Two demethylating drugs, 5-azacy-
tidine (5-aza-CR) and 5-aza-29-deoxycytidine (5-aza-dC), already
have been approved by the Food and Drug Administration
(FDA) for the treatment of myelodysplastic syndrome.6 7
More than 40 years ago, both compounds were developed
as classical cytostatic agents,8 but later were found to work
indirectly on tumour cell proliferation by inhibiting DNA
methyltransferases (DNMTs) in vitro and in vivo. Interestingly,
5‑aza-CR, but not 5-aza-dC, also inhibits cellular protein
synthesis, caused by blocking rRNA formation and disaggrega-
tion of polyribosomes.9e11
The current interest in TRAIL signalling is reﬂected by the
fact that at least six different TRAIL receptor-targeted thera-
peutics (antibodies/recombinant proteins) have already been
tested in clinical trials.12 Speciﬁcally, a huge effort has been
undertaken to discover substances that sensitise HCC cells
which as inherently resistant to TRAIL, such as classical
chemotherapeutics,13 adenoviral gene transfer,14 proteasome,
c-Jun N-terminal kinase (JNK) or histone deacetylase inhib-
itors.15e17 Recently, approaches combining demethylating drugs
together with TRAIL have been investigated.18e21 However,
these studies mostly focused on 5-aza-dC and did not speciﬁcally
investigate 5-aza-CR’s inherent mode of action as a cellular
protein synthesis inhibitor.
In contrast, our work unravels new mechanisms and opens
up new perspectives for the clinical application of 5-aza-CR by
demonstrating that 5-aza-CR mediates a sensitisation of hepa-
toma, renal, colon and pancreatic cancer cells to TRAIL in a p53-
independent fashion. As a possible mechanism, an inhibition of
cellular protein synthesis is suggested, which was found also to
comprise the translational inhibition of the antiapoptotic factor
FLICE inhibitory protein (FLIP). Importantly, a detailed char-
acterisation of this combinatorial approach on primary human
hepatocytes, liver tissue slices and non-malignant colon cells did
not show signs of toxicity. Finally, employing a chorioallantoic
membrane (CAM) assay with hepatoma cells, we could also
prove a profound antitumour acitivity in vivo. Therefore, 5-aza-
CR seems to constitute an ideal TRAIL sensitiser candidate for
further clinical evaluation in the context not only of HCC
treatment, but also of other TRAIL-resistant tumour entities.
MATERIALS AND METHODS
Cell culture
Human-derived tumour cell lines HepG2, Hep3B and A-498 were
obtained from the German Collection of Microorganisms and
Cell Cultures (DSMZ, Braunschweig, Germany) and cultured in
Dulbecco’s modiﬁed Eagle’s medium (DMEM; Lonza Bioscience,
Verviers, Belgium) with 10% fetal calf serum (FCS) and 2 mmol/l
L-glutamine (Life Technologies, Rockville, Maryland, USA).
Primary human hepatocytes (PHHs) from different donors were
provided by T.S. Weiss according to the guidelines and informed
consent of the charitable state-controlled Human Tissue & Cell
Research Foundation HTCR (http://www.htcr.de) and cultured
as described22; in brief, in DMEM with 100 U/ml penicillin and
streptomycin (Serva, Heidelberg, Germany), 2 mmol/l L-gluta-
mine, 18.8 mg/ml hydrocortisone (Merck, Darmstadt, Germany)
and 1.68 mU/ml insulin (Novo Nordisk, Bagsvaerd, Denmark).
Reagents
5-Aza-CR (Sigma-Aldrich, Taufkirchen, Germany), 5-aza-dC
(Sigma-Aldrich), cycloheximide (CHX; Carl Roth, Karlsruhe,
Germany), ﬂuorescein diacetate (Sigma-Aldrich), staurosporine
(STS; Biomol, Hamburg, Germany), sulforhodamine B (SRB;
Sigma-Aldrich), soluble recombinant human TRAIL (residues
114e281; Calbiochem, Schwalbach, Germany).
Fluorescence-activated cell sorting (FACS) analysis
HepG2 (7.53104 cells/well) were seeded in 24-well plates. After
incubation cells were washed once in phosphate-buffered saline
(PBS; 10 min; 1500 rpm). Pellets were resuspended in 300 ml of
hypotonic staining buffer containing 0.02 mg/ml propidium
iodide and incubated on ice for 30 min. Flow cytometry was
performed (FACS Calibur, Becton Dickinson, Heidelberg,
Germany) by using Cell QuestTM software.
RNA interference
HepG2 cells were transfected in 24-well plates (7.53104 cells/
well) using Lipofectamine RNAiMax (Invitrogen, Karlsruhe,
Significance of this study
What are the new findings?
< The demethylating drug 5-aza-CR leads to a rapid breakdown
of tumour-protecting factors which sensitises resistant cancer
cells for an application of apoptosis-inducing therapeutics
such as the cytokine TRAIL.
< Surprisingly, we found out that the sensitisation to TRAIL is
not mediated via a suspected epigenetic modulation of
methylation events but rather by a 5-aza-CR-inherent shut-
down of cellular protein biosynthesis.
< Primary human hepatocytes, liver tissue slices isolated from
different human donors and non-malignant colon cells did not
show relevant signs of toxicity during a combination
treatment with 5-aza-CR and TRAIL, implying a broad
therapeutic window for this novel approach.
< Thus, 5-aza-CR but not the closely related compound 5-aza-dC
harbours a dual antitumour activity in apoptosis/TRAIL-
resistant cancer cells by (1) inducing a breakdown of
tumour-protecting factors, thereby enabling the execution of
apoptosis, and (2) in the remaining cancer cells having an
epigenetic targeted approach by a reversion of the
malignancy-associated methylation phenotype.
How might it impact on clinical practice in the foreseeable
future?
< Worldwide, a huge effort is being made to identify clinically
applicable drugs which are able to downregulate
apoptosis-protecting factors, these being a major hallmark in
cancer cells.
< The basic concept of using a well-known drug to overcome
resistance to treatment which harbours a considerable
antitumour activity by a completely different mechanism on
its own is quite attractive for translation into clinical trials in
the near future.
< The discovery that the 5-aza-CR-inherent activity to block
protein biosynthesis sensitises so far resistant cancer cells,
such as HCC, renal, colon or pancreatic cancer, to TRAIL or
even other apoptosis-mediated therapeutic strategies will
strongly impact the design of future clinical trials that include
epigenetic active compounds. In contrast to the closely
related epigenetic drug 5-aza-dC, the application of 5-aza-CR
adds a further molecular mechanism in the fight against
cancer. 5-Aza-CR opens up the possibility to use TRAIL or
TRAIL-related compounds even in tumours harbouring
a primary resistance.
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Germany). A set of four predesigned small interfering RNAs
(siRNAs; Qiagen, Hilden, Germany) matching human FLIP RNA
was transfected (ﬁnal concentration 25 nmol/l). A further set of
four siRNA sequences without homology to any known
mammalian RNA was applied as a negative control. All values
were referred to untreated control cells (% control).
Real-time cell proliferation assay
HepG2 cells (53103 cells/well) were seeded in 96-well plates
(E-Plate 96, Roche Applied Science, Mannheim, Germany). Real-
time dynamic cell proliferation was monitored at 2 h intervals
during 48 h using the xCELLigence system (Roche Applied
Science). Cell index values were calculated using the RTCA
Software (1.0.0.0805). All curves were normalised at the begin-
ning of the treatment period applying the RTCA Software.23 24
Human tissue slicing
Human liver resections from three donor patients were obtained
from the Department of General, Visceral and Transplant
Surgery, University Clinic Tuebingen, according to the guidelines
of the local Ethics Committee with informed consent. Precision-
cut liver slices were prepared as described in the Supplementary
Materials and methods section online.
CAM assay
CAM assay was done as described previously.25 26 Brieﬂy, 13106
HepG2 cells were implanted on fertilised chicken eggs on day 8
of incubation and were treated with 5 mmol/l 5-aza-CR and/or
100 ng/ml TRAIL for 4 days, sampled with the surrounding
CAM, ﬁxed in 4% paraformaldehyde, parafﬁn embedded, cut in
5 mm sections and histologically analysed using 1:1 haematox-
ylin and 0.5% eosin. Images were digitally recorded at a magni-
ﬁcation of 32 with an A370 microscope (Olympus, Center
Valley, Pennsylvania, USA). Tumour areas were analysed with
ImageJ digital imaging software (download from the NIH
website, http://rsbweb.nih.gov/ij/download.html).
Statistical analysis
Statistical analyses were performed with either Student t test or
one-way analysis of variance (ANOVA) Bonferroni post-test
using GraphPad Prism version 4.00 (GraphPad Software, San
Diego, California, USA). A p value of <0.001 is indicated in the
ﬁgures by an asterisk.
RESULTS
5-Aza-CR but not 5-aza-dC mediates a rapid sensitisation of
hepatoma cells to TRAIL
Combined short-term (24 h) incubation of TRAIL-resistant
HepG2 human hepatoblastoma cells with 5-aza-CR and TRAIL
revealed a signiﬁcant increase of apoptosis as indicated by
propidium iodide-positive cells in sub2N-DNA FACS quantiﬁca-
tion (ﬁgure 1A; time course in the upper ﬁgure, statistical analysis
at 24 h in the lower ﬁgure). In contrast, no apparant change was
observed under combined treatment with 5-aza-dC and TRAIL or
monotherapeutic application of either substance alone.
To reassess these results, the effects of 5-aza-CR and 5‑aza-dC
were further studied by ﬂuorescein diacetate assays, now addi-
tionally employing the hepatoma cell line Hep3B (ﬁgure 1B).
Again, a combined treatment with 5-aza-CR and TRAIL induced
a highly signiﬁcant decline in the number of both HepG2 and
Hep3B cells of >50%, whereas 5-aza-dC again was not able to
overcome resistance to TRAIL; also monotherapeutic applica-
tion of either substance alone did not lead to any reduction in
hepatoma cell survival.
Based on the observation that 5-aza-CR but not 5-aza-dC
possesses the ability to sensitise hepatoma cells to TRAIL within
a short incubation period not exceeding 24 h, we hypothesised
that DNMT inhibition, which is known to require much more
‘effector time’,8 18 19 could not be the molecular mechanism
responsible for this effect. Thus, we assumed that the earlier
described additional inherent activity of 5-aza-CR in inhibiting
protein synthesis9e11 might be the main mechanism responsible
for this rapid sensitisation to TRAIL.
General inhibition of protein biosynthesis by 5-aza-CR or CHX
induces a downregulation of the antiapoptotic factor FLIPL
CHX is well known to block translational elongation, resulting
in a reversible inhibition of protein biosynthesis at the ribosomal
level, comparable with the effects of 5-aza-CR.
Figure 1 Tumour necrosis factor-related apoptosis-inducing ligand
(TRAIL) in combination with 5-azacytidine (5-aza-CR), but not with
5-aza-29-deoxycytidine (5-aza-dC), induces cell death in human-derived
hepatoma cells. (A) HepG2 hepatoblastoma cells were incubated with
20 mmol/l 5-aza-CR or 20 mmol/l 5-aza-dC and/or 10 ng/ml TRAIL (upper
diagram). After 6, 12 and 24 h, cells were stained with propidium iodide
and the fraction of apoptotic cells was determined by fluorescence-
activated cell sorting (FACS) analysis (sub2N-DNA). Statistical analysis
was performed at 24 h (lower diagram); shown are here the mean of
three independent experiments 6SD. (B) HepG2 and Hep3B cells were
treated for 24 h with either 20 mmol/l 5-aza-CR, 20 mmol/l 5-aza-dC and
10 ng/ml TRAIL alone or the combination thereof. Cell survival was
investigated by fluorescein diacetate assay. All values (% control) were
referred to untreated control cells. Shown are the mean of three
independent experiments 6SD. (A, B) *p<0.001, one-way analysis of
variance Bonferroni post-test; significance is indicated where the
combination treatment of 5-aza-CR and TRAIL was more efficient than
each treatment alone.
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To further support the hypothesis of an inhibition of protein
synthesis by 5-aza-CR in hepatoma cells, we next performed
a ﬂow cytometry-based analysis of HepG2 cells transiently
transfected with the enhanced green ﬂuorescent protein (EGFP)
reporter gene. Again, within only 24 h, we found a dose-
dependent shut-down of EGFP expression mediated by both
compounds, CHX or 5-aza-CR, but not by 5-aza-dC (ﬁgure 2A).
Of note, the combined treatment of both cell lines, HepG2 and
Hep3B, with CHX and TRAIL (ﬁgure 2B) was found to yield
a decline in the surviving cell fraction similar to the results of the
incubation with 5-aza-CR and TRAIL (ﬁgure 1B), whereas no
signiﬁcant reduction was observed under monotherapy with
CHX or TRAIL alone.
It has been shown that CHX treatment of hepatoma cells
results in a reduction of the intracellular level of the anti-
apoptotic FLIP, and that FLIP downregulation is able to sensitise
for high doses of TRAIL (100 ng/ml).27 Thus, it was of interest
whether CHX and 5-aza-CR share a common mechanism
regarding FLIP, which was examined by a western blot analysis
(ﬁgure 2C). In line with the pattern of reaction to CHX, treat-
ment with 5-aza-CR resulted in a clear reduction of the
intracellular concentration of the long form of FLIP (FLIPL).
Incubation of HepG2 cells with different concentrations of
5-aza-dC had no comparable effect on FLIPL (Supplementary
ﬁgure 1A online). In addition, the 5-aza-CR-mediated down-
regulation of protein synthesis seems also to affect other
important cellular proteins such as p53 (Supplementary ﬁgure 1B
online).
To functionally verify the importance of FLIPL in our setting
speciﬁcally applying low doses of TRAIL (10 ng/ml), a speciﬁc
knockdown of endogenous FLIP in HepG2 cells was performed
via transfection of FLIP siRNA (ﬁgure 2D). Interestingly, this
singular knockdown of FLIP was able to induce a signiﬁcant
sensitisation towards TRAIL-mediated cytotoxicity, whereas
the control transfection with a set of non-coding siRNAs and
co-treatment with TRAIL did not show an increase in lactate
dehydrogenase (LDH) release as a surrogate parameter for
toxicity (ﬁgure 2D). Notably, the combined incubation of 5-aza-
CR and TRAIL led to a similar increase in LDH release which
could not be further enhanced by siRNA-mediated inhibition of
FLIP (ﬁgure 2D, white bars). It is concluded from these experi-
ments that downregulation of FLIPL by 5‑aza-CR or CHX can be
regarded as a major mechanism to overcome TRAIL resistance in
human hepatoma cells.
Figure 2 Hepatoma cell sensitisation to tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) by inhibition of protein synthesis and
reduction of intracellular levels of FLICE inhibitory protein (FLIP). (A) The decrease of enhanced green fluorescent protein (EGFP) fluorescence by
inhibition of protein translation displayed as median fluorescent intensity of HepG2 cells transiently transfected with EGFP and simultaneously treated
with increasing concentrations of either 5-aza-29-deoxycytidine (5-aza-dC), 5-azacytidine (5-aza-CR) or cycloheximide (CHX). The cell population
marked as EGFP served as the control. Fluorescence-associated cell sorting (FACS)-based analysis on the intensity of emerging fluorescence was
performed 24 h after transfection. Shown are means of three independent experiments6SD. (B) HepG2 and Hep3B cells were cultured in the presence
or absence of 10 ng/ml TRAIL and/or 10 mg/ml CHX. Cell survival was detected by fluorescein diacetate assay. All values were referred to untreated
control cells (% control). Shown are the mean of three independent experiments 6SD. *p<0.001, one-way analysis of variance (ANOVA) Bonferroni
post-test with a significance of the combinatorial treatment being more efficient than each treatment alone. (C) FLIPL expression in HepG2 and Hep3B
cells after incubation with 20 mmol/l 5-aza-CR or 1 mg/ml CHX for 12 h was examined by western blot analysis. Equal protein loading was verified by
vinculin staining on the same blot (upper band). FLIPL levels were estimated by performing a densitometric analysis; values are shown relative to
untreated controls. (D) HepG2 cells were transfected with either a set of non-coding control small interfering RNA (siRNA; NC) or FLIP-targeted siRNA
(FLIP). At 48 h after transfection cells were incubated for 24 h with 20 mmol/l 5-aza-CR and/or 10 ng/ml TRAIL. Cytotoxicity was investigated by
measurement of relative lactate dehydrogenase (LDH) release; all values were referred to untreated control cells (% control). Shown are the mean of
three independent experiments 6SD. *p<0.001, one-way ANOVA Bonferroni post-test, n.s., no significant difference.
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Dual antitumour effect of 5-aza-CR and TRAIL by an early
caspase activation followed by an inhibition of cellular
proliferation in surviving tumour cells
Epigenetic treatment of cancer cells based on drugs that alter the
methylation pattern in tumour cells by DNMT inhibition are
generally thought to require at least one replication round of the
tumour cells before therapeutic effects occur.8 18 19 According to
our results in hepatoma cells, therapeutic combination of 5-aza-
CR with TRAIL habours a dual antitumour activity, based on (1)
a rapid induction of apoptotic cell death, independent of an
epigenetic modulation, followed by (2) an alteration of meth-
ylation events in surviving cancer cells in combination with an
enduring suppression of cellular protein synthesis. To support
this hypothesis further, time course experiments of both caspase
activation and cellular proliferation were performed.
Caspase activation was investigated for the initiator caspase-8
and the executioner caspase-3/7 by ﬂuorimetric caspase activity
assays (ﬁgure 3A,B). Already after 6 h, but more pronounced
after 12 h of combined treatment with 5-aza-CR and TRAIL,
a signiﬁcant induction of caspase-8 (ﬁgure 3A) and caspase-3/7
(ﬁgure 3B) could be detected. This increase of activation was
already terminated within the ﬁrst 24 h of treatment. Incuba-
tion with 5-aza-CR or TRAIL alone did not show any relevant
caspase activity at any point in time. Notably, incubation with
STS, a rapid and strong inducer of apoptosis in hepatoma cells,28
showed a similar reaction pattern with only marginally higher
caspase activity values. Additional real-time monitoring of
caspase-3 activity within live cells after 12 h of treatment also
demonstrated caspase activation after co-treatment, but not by
incubation with each substance alone (Supplementary ﬁgure 2
online).
To monitor cellular proliferation in real-time under various
treatment schedules, the xCELLigenceTM system was used
(ﬁgure 3C) to obtain cell index curves by a continuous measure-
ment of the electrode impedance in each well. This parameter
reﬂects the biological status of the cell layer, including cell
viability and proliferation, and is depicted by the normalised cell
index.23 24 Combination treatment of 5-aza-CR and TRAIL
induced a rapid and substantial reduction of the normalised cell
index, occurring within a 6e12 h time span (ﬁgure 3C). In
contrast, HepG2 cells treated with 5-aza-CR alone or TRAIL
alone displayed a 24 h proliferation pattern quite similar to that
of untreated control cells. Between 24 and 48 h, a reduced
proliferation signal could be detected for 5-aza-CR-treated cells,
which most probably reﬂects the well-known kinetics of epige-
netic modulation due to DNMT inhibition together with ongoing
inhibition of cellular protein synthesis (ﬁgure 3C). As a positive
control for cell death, detergent treatment with Triton X-100
induced a direct and very rapid decline in the normalised cell
index. Thus, after a rapid decline due to 5-aza-CR-mediated
sensitisation to TRAIL, surviving hepatoma cells are then exposed
to 5-aza-CR’s dual effects of DNMT and protein biosynthesis
inhibition, imposing a second hit on the hepatoma cells.
Lack of toxicity of the combination of 5-aza-CR and
TRAIL for non-malignant cell types
To minimise unwanted side effects that might limit translation
of new treatment strategies into clinical applications, toxicity
studies are inevitable. Especially in the context of the liver, each
new application strategy employing TRAIL has to be carefully
tested for its potential liver toxicity. Thus, we employed PHHs
and human-derived liver tissue cultures, so-called precision-cut
liver slices,29 to investigate both (1) cellular integrity of non-
malignant cells and (2) severity of cellular damage by LDH and
aspartate aminotransferase (AST) release assays.
Applying two different doses of TRAIL (10 and 100 ng/ml),
a strong increase of LDH and AST release into the supernatant
during combined 5-aza-CR and TRAIL treatment was found in
Figure 3 Time course of caspase
activation and real-time measurement of
cellular proliferation. (A, B) HepG2 cells
were treated with 20 mmol/l
5-azacytidine (5-aza-CR) and/or
10 ng/ml tumour necrosis factor-related
apoptosis-inducing ligand (TRAIL);
staurosporine (STS) was used as
a positive control. (A) Initiator caspase-
8 and (B) effector caspase-3/7 activities
were determined after 6, 12 and 24 h of
treatment. Shown are the mean of three
independent experiments. *p<0.001,
one-way analysis of variance Bonferroni
post-test; significance of caspase-8 and
caspase-3/7 activation is indicated
where the combination of 5-aza-CR and
TRAIL was more efficient than each
treatment alone. (C) Real-time analysis
of cell proliferation by a continuous
measurement of the electrode
impedance in each well using the
xCELLigenceTM system. HepG2 cells
were treated over 48 h with 20 mmol/l
5-aza-CR and/or 10 ng/ml TRAIL. As
a positive control 0.1% Triton X-100
was used. All values were normalised to
an initial time point. 0 h represents the
beginning of the treatment. Shown are
the mean values of the normalised cell
index of three independent experiments.
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HepG2 hepatoblastoma cells at both concentrations (ﬁgure 4
and Supplementary ﬁgure 3 online). In contrast, human-derived
liver slices from different donors did not show signiﬁcant
increases of ASTor LDH release, even under employment of high
doses of TRAIL (ﬁgure 4).
The 5-aza-CR-mediated sensitisation of tumour cells to
TRAIL occurred at 10 ng/ml. At this concentration no toxic
effect could be detected in PHHs concerning the release of LDH
or AST (Supplementary ﬁgure 3 online). Employing a ﬂuorescein
diacetate assay, PHHs did not show a reduced survival under
10 ng/ml TRAIL and 20 mmol/l 5-aza-CR (ﬁgure 5A, left side).
Using an SRB assay, which measures cellular protein content as
a surrogate marker for viability, 5-aza-CR in combination with
TRAIL was not different from TRAIL treatment alone in PHHs
(ﬁgure 5, right side). However, a slight reduction of the PHH
viability was detected in each sample with TRAIL. Neither LDH
nor AST release was increased in PHHs under these treatment
conditions (Supplementary ﬁgure 3 online), which excluded
a substantial toxicity of the treatments. Even employing
a 10-fold increased concentration of TRAIL, no AST and only a
slight but not signiﬁcant (p>0.05, one-way ANOVA Bonferroni
post-test) LDH release from PHHs occurred (ﬁgure 4A, middle
graphs). Treatment with Triton X-100 was used for PHHs or
liver slices as a surrogate marker to determine the maximum
obtainable amount of LDH or ASTrelease, thereby reﬂecting the
heterogeneity of different liver sample donors with different
clinical histories. Taken together we conclude that 5-aza-CR is
not mediating a sensitisation of non-malignant liver cells to
TRAIL, even with high concentrations of TRAIL.
Next, a possible activation of executioner caspases in PHHs
under 5-aza-CR and TRAIL co-treatment was investigated. In
clear contrast to the previous experiments (ﬁgure 3B), no
increase of caspase activity could be detected in PHHs at any
point in time, whereas incubation with STS as a positive control
Figure 4 Lack of toxicity of
5-azacytidine (5-aza-CR) in combination
with tumour necrosis factor-related
apoptosis-inducing ligand (TRAIL) on
primary human hepatocytes or human-
derived liver tissue slices. HepG2 cells,
primary human hepatocytes (PHHs) and
precision-cut liver slices from three
different donors (PHH and liver slices)
were incubated for 24 h with 20 mmol/l
5-aza-CR and/or 100 ng/ml TRAIL.
Release of (A) lactate dehydrogenase
(LDH) or (B) aspartate aminotransferase
(AST) into the supernatant was
analysed by ELISA. All values were
referred to untreated cells (% control).
Shown are the mean of three independent experiments 6SD. *p<0.001, one-way analysis of variance Bonferroni post-test. No statistically significant
toxicity could be detected for the combinatorial treatment of PHHs or liver slices.
Figure 5 Pattern of reaction of
primary human hepatoytes (PHHs) to
combined treatment with 5-azacytidine
(5-aza-CR) and tumour necrosis factor-
related apoptosis-inducing ligand
(TRAIL) (A) PHHs from three different
donors were incubated with 20 mmol/l
5-aza-CR and/or 10 ng/ml TRAIL. Cell
survival was determined in a fluorescein
diacetate assay (left graph). The same
PHHs were used for a sulforhodamine B
assay to prove cell viability (right
graph). The mean of three independent
experiments 6SD are shown. (B)
Caspase-3/7 activity was investigated
6, 12 and 24 h after the initiation of the
indicated treatments. Staurosporine
(STS; 5 mmol/l) was used as a positive
control. (A, B) No statistical significant
toxicity in the (A) fluorescein diacetate
assay or (B) caspase activation could
be detected for the combinatorial
treatment of PHHs by a one-way
analysis of variance Bonferroni post
test. (C) Western blot analysis to
assess the amount of the long form of
FLICE inhibitory protein (FLIPL) in PHH
cellular lysates at different points in
time. Equal protein loading was verified
by vinculin staining (upper band).
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for apoptosis induction clearly induced caspase activity up to
12-fold (ﬁgure 5B). Finally, we examined whether the treatment
of PHHs with 5‑aza-CR has any inﬂuence on intracellular FLIPL
protein levels. In contrast to the cell lines HepG2 and Hep3B
(ﬁgure 2C), PHHs showed no alteration of the FLIPL protein
level either under 5-aza-CR or CHX treatment at any point in
time (ﬁgure 5C).
To further evaluate possible toxic effects in another non-
malignant tissue context, two non-malignant colon cell lines
CCD-18Co (Supplementary ﬁgures 4 and 5 online) and CCD
841 CoN (Supplementary ﬁgures 6 and 7 online) were investi-
gated using 10 and 100 ng/ml TRAIL. With the exception of
caspase-3/7 activity in CCD 841 CoN cells incubated with the
high concentration of TRAIL (100 ng/ml) or the combination of
TRAIL and 5-aza-CR, no signs of toxicity could be detected in
viability assays, LDH release or caspase-3/7 activation.
In vivo activity of 5-aza-CR and TRAIL
Subsequently, the in vitro characterised treatment schedules
were further investigated in vivo in a CAM assay with HepG2
cells (ﬁgure 6). Representative images of the H&E-stained
sections demonstrate a profound reduction of the tumour mass
mediated by combined 5-aza-CR and TRAIL treatment, whereas
either monotherapeutic approach had no relevant effect on the
tumour size (ﬁgure 6A). For statistical evaluation, sections were
digitally recorded and tumour areas were analysed (ﬁgure 6B). In
line with our previous in vitro experiments, the combinatorial
treatment group was found to be statistically signiﬁcantly
different from each single and the untreated control group.
Thus, a clear effectiveness of combined 5-aza-CR and TRAIL
treatment was also demonstrated in an in vivo model.
5-Aza-CR-mediated TRAIL sensitisation can be expanded to
renal, pancreatic and colon cancer cells
The sensitisation of TRAIL-resistant tumour cells by CHX has
been described for other tumour entities, too. Therefore, it was
reasonable to assume, that the observed TRAIL sensitisation by
5-aza-CR in hepatoma cells might be a more general mechanism.
To address this question, we also studied viability, survival and
caspase activity in the renal cancer cell (RCC) line A-498, which
is included in the NCI60 human tumour cell line panel. A-498 is
known to exhibit a resistance to TRAIL-induced apoptosis,
which can be overcome by a knockdown of FLIP.30 We detected
a signiﬁcant decline of both the viability and cellular survival
after a short incubation with 5-aza-CR and TRAIL (ﬁgure 7A).
In comparison, treatment with 5-aza-dC did not sensitise for
TRAIL (ﬁgure 7B), but the established protein synthesis inhib-
itor CHX did (ﬁgure 7C). Furthermore, in analogy to the caspase
activation in HepG2 cells, the activation of caspases in A-498
cells was examined at an early time point (12 h) after initiation
of treatment (ﬁgure 7D). Activities of both the initiator caspase-
8 and the executioner caspase-3/7 were found to be signiﬁcantly
elevated, while incubation with 5-aza-CR or TRAIL alone did
not show any relevant activity. These observations could be
expanded to pancreatic cancer cells MIA PaCa-2 (Supplementary
ﬁgure 8 online) as well as colon cancer cells HCT-116 and COLO
205 (Supplementary ﬁgures 9 and 10 online). Taken together, the
concept of 5-aza-CR’s dual activity enabling TRAIL resistance to
be overcome could be regarded as a general mechanism in
different tumour entities.
DISCUSSION
Human hepatoma cells display a marked resistance to conven-
tional cytostatic agents, with the exception of the oral
multikinase inhibitor sorafenib,2 but still alternative therapy
strategies are urgently needed.31
In the present study, we succeeded in overcoming the resis-
tance to TRAIL in vitro and in vivo by using 5-aza-CR, one of the
currently most advanced drugs for epigenetic cancer treatment.8
Most strikingly, 5-aza-CR was found to restore sensitivity to
TRAIL in tumour cells very quickly (within 24 h) and effectively.
Importantly, the combined 5-aza-CR/TRAIL treatment
exhibited no toxic effect in human-derived primary hepatocytes
and liver tissue slices from different donors or non-malignant
colon cell lines. Furthermore, we were able to ﬁnd several lines of
evidence that this rapid sensitisation to TRAIL is not mediated
via epigenetic mechanisms, but due to a currently rarely
discussed, but well-known ‘side’ effect of 5-aza-CRdthat is, the
reversible disruption of cellular protein biosynthesis. The intra-
cellular metabolisation and mode of action as well as the TRAIL
signal transduction are summarised in ﬁgure 8.
In contrast, the closely related compound 5-aza-dC possesses
a deoxyribose backbone, which excludes the possibility of
Figure 6 In vivo sensitisation to tumour necrosis factor-related
apoptosis-inducing ligand (TRAIL)-induced cell death by 5-azacytidine
(5-aza-CR). (A, B) HepG2 cells were seeded on the chorioallantoic
membrane (CAM) of chicken embryos and treated with 5 mmol/l
5-aza-CR and/or 100 ng/ml TRAIL. Tumour growth was analysed using
H&E-stained paraffin sections of the CAM. Representative pictures of
H&E-stained sections of the CAM (A) and measured tumour area (B) are
shown. Error bars indicate the means 6SD of nine samples per group
from two independent experiments. *p<0.001, Student t test.
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incorporation into cellular RNA and subsequent disruption of
cellular protein biosynthesis. This differential feature is one of
the main reasons why 5-aza-CR is clinically regarded as the
more toxic DNMT inhibitor compound. Furthermore, 5-aza-CR
only exhibits a poor conversion rate into its DNMT-inhibiting
deoxyribonucleotide form,8 resulting in a less potent inhibition
of cellular DNMTs than found for similar concentrations of
5-aza-dC. For both reasons, 5-aza-dC currently is the most
established substance among the DNMT inhibitor compound
family. Taking this into account, it is not surprising that present
studies on the combination of TRAIL and DNMT inhibitor
compounds focus almost exclusively on the usage of 5-aza-dC,
for instance in breast cancer, glioblastoma or neuro-
blastoma.18e20 Hence, studies which applied 5-aza-dC in the
context of TRAIL sensitisation have been prone to miss the early
effect of a decrease in regulatory cellular proteins.
In line with our result of a 5-aza-CR-mediated sensitisation to
TRAIL, a recent report focusing on death receptor-induced
apoptosis in general describes a sensitisation by 5-aza-CR
towards death receptor-induced apoptosis.21 However, from
a clinical perspective there are two major limitations of this work
that would interfere substantially with a clinical translation of
our suggested approach. First, a rapid killing of PHHs from
a single donor under the combination treatment was reported,
but in this case an artiﬁcially tagged TRAIL preparation had been
applied which had been attributed to an enhanced toxicity in
primary cells in previous studies.32 33 Secondly, the authors
suggested that TRAIL sensitisation might be p53 dependent,
which would be highly relevant due to the fact that the p53
pathway is impaired in the majority of HCC.34 In contrast to
that hypothesis, we detected a signiﬁcant reduction of cell
survival for the different tumour cell lines Hep3B, MIA PaCa-2
and COLO 205, when treated with 5-aza-CR and TRAIL. This is
most important, because the hepatoma cell line Hep3B is known
to be p53 deﬁcient, whereas MIA PaCa-2 and COLO 205 have
a mutated p53.35e37 Moreover, p53 is a cellular protein with
a short half-life of only 15e20 min.38 Due to the rapid breakdown
of protein biosynthesis by 5-aza-CR treatment, we detected
a decline in the p53 levels in the p53 wild-type tumour cell line
HepG2 after 12 h (Supplementary ﬁgure 1B online). As an addi-
tional experiment to verify functionally the independence of p53,
a speciﬁc knockdown of endogenous p53 in HepG2 cells was
performed via transfection with p53 siRNA. No signiﬁcant
differences between transfected cells with non-coding siRNAs
and p53 siRNAs were detected in the LDH toxicity assay after
co-treatmentwith 5-aza-CRandTRAIL (Supplementaryﬁgure 11
online). These investigations strongly indicate a p53-independent
mode of action.
Several levels of resistance to TRAIL have been described
so far.39 Considering the most upstream level in the signal
Figure 7 5-Azacytidine (5-aza-CR)-
mediated sensitisation of renal cancer
cells to tumour necrosis factor-related
apoptosis-inducing ligand (TRAIL)-
induced apoptosis. (A, B) A-498 renal
cell carcinoma (RCC) cells were
incubated with (A) 20 mmol/l 5-aza-CR
and (B) 20 mmol/l 5-aza-29-
deoxycytidine (5-aza-dC) and/or 10 ng/
ml TRAIL. A fluorescein diacetate assay
to detect cell survival was performed
(left graph). Cell viability was
determined in a sulforhodamine B assay
(right graph), with 100% viability
representing the optical density of
untreated cells. (C) The same
experimental set-up but with 10 mg/ml
cycloheximide (CHX) instead of 5-aza-
CR to determine survival and viability of
the cells was used. (D) Caspase-8 (left
graph) and caspase-3/7 activity (right
graph) was investigated 12 h after the
initiation of the treatment. Staurosporine
(STS; 5 mmol/l) was used as a positive
control. (AeD) The means of three
independent experiments (AeC) 6SD
are shown. *p<0.001, one-way analysis
of variance Bonferroni post-test;
significance is indicated where the
combination treatment of 5-aza-CR and
TRAIL was more efficient than each
treatment alone.
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transduction of TRAIL in tumour cells, we excluded an upre-
gulation of the proapoptotic receptors DR4 or DR5 by 5-aza-CR
as a possible mechanism of sensitisation of TRAIL (Supple-
mentary ﬁgure 12 online). Besides HCC, other tumour entities
such as prostate or renal cancer have been reported to display
a FLIP-mediated resistance to TRAIL.30 40 A study in human
renal carcinoma cells30 applying CHX and our own results
reinforce the importance of consistency of protein synthesis
in tumour cells in order to maintain a TRAIL resistance
phenotype. It is important to note that even though CHX and
5-aza-CR operate in this particular situation with a related
mode of action, any therapeutic application of CHX in vivo
is deﬁnitely excluded, due to the fact that CHX exerts
dramatic toxic side effects. In contrast, 5-aza-CR is approved for
clinical application and possesses the additional capacity to
modulate the epigenetic pattern of cancer cells as a potent
DNMT inhibitor compound, which suggests that 5-aza-CR
might be an ideal combination partner in therapeutic settings
that require the inhibition of tumour-protecting proteins to
overcome treatment resistance.
In the context of TRAIL, hepatotoxicity has repeatedly been
an important issue.32 33 Therefore, we applied, in addition to
non-malignant colon cell lines, two different toxicity screening
approaches with human-derived hepatocytes: PHHs and liver
slices from surgically resected human specimens. As an impor-
tant result and in clear contrast to the tested tumour entities, we
could not detect an 5-aza-CR-mediated sensitisation to TRAIL
in any of the three toxicity models applying enzyme release,
caspase activity and cell survival assays, paving the way for
a possible clinical evaluation of our concept. Interestingly,
a recently reported phase I dose-escalating study with TRAIL in
humans did not show any relevant liver toxicity.41 The
concentrations in that study were much higher than in our cell
culture systems, reaching peak concentrations of up to 279 mg/
ml. Therefore, liver toxicity seems not to be a major problem of
TRAIL itself in humans. However, preliminary data should be
kept in mind when designing phase I/II clinical trials involving
TRAIL, which suggested that patients with an active hepatitis C
infection or a fatty liver disease might be prone to liver-related
toxicities.42 43
5-Aza-CR is well known for its epigenetic mode of action due
to a strong inhibition of DNMT enzymes. Furthermore, several
reports found that 5-aza-CR induces a G2/M cell cycle arrest in
different tumour cells.44 45 In fact, epigenetic alterations are an
important hallmark of HCC,3e5 for example the gene for
suppressor of cytokine signalling (SOCS-1) is known to be
methylated in most HCCs and its methylation-induced inacti-
vation has been attributed an important role in the development
of HCC.46 We previously could show that incubation of HepG2
hepatoblastoma cells for 48 h with 5 mmol/l 5-aza-dC efﬁciently
demethylates the SOCS-1 gene.47 Regarding 5-aza-CR, we also
found a profound demethylation of SOCS-1 in HepG2 cells by
applying 5 mmol/l for 48 h (data not shown), which underlines
the capacity of 5-aza-CR for antitumour efﬁcacy at several
independent levels in the context of HCC.
In conclusion, the proposed combination of 5-aza-CR and
TRAIL beneﬁts from different modes of action. Whereas 5-aza-
CR initially blocks protein biosynthesis and thereby restores the
sensitivity for TRAIL-induced apoptosis, it subsequently also
demethylates cellular DNA, resulting in an activation of silenced
regulatory genes. This new antitumour strategy might be
a therapeutic option not only in HCC, but also for other tumour
entities displaying a resistance to TRAIL and an accumulation of
hypermethylated CpG islands within cellular control genes, for
example renal, colon or pancreatic cancer.
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Figure 8 Dual mode of action of 5-azacytidine (5-aza-CR): demethy-
lation of cellular DNA and inhibition of protein biosynthesis in tumour
necrosis factor-related apoptosis-inducing ligand (TRAIL)-resistant
tumour cells. The constitutive expression of intracellular antiapoptotic
factors such as FLIPL protects tumour cells such as hepatoma cells
against TRAIL-induced apoptosis. Following cell entry of 5-aza-CR and its
conversion to 5-aza-CTP, incorporation into RNA takes place, resulting in
a rapid and selective inhibition of 18S and 28S RNA formation, leading to
a block in the synthesis of functional ribosomes. The inhibition of protein
synthesis is postulated to induce a quick decrease of regulatory cellular
proteins, such as the long form of FLICE inhibitory protein (FLIPL),
thereby restoring sensitivity to TRAIL in hepatoma cells. Simultaneously,
5-aza-CR is converted by the ribonucleotide reductase into the
corresponding deoxynucleotide 5-aza-dCTP, this being a prerequisite for
incorporation into cellular DNA as a prerequisite for its epigenetic mode
of action. This enzymatic step is not required for the related drug 5-aza-
29-deoxycytidine (5-aza-dC), which is directly phosphorylated to 5-aza-
dCTP after cell entry, without the ability for incorporation into RNA.
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